Urinary Proteomics Based on Capillary Electrophoresis-Coupled Mass Spectrometry in Kidney Disease: Discovery and Validation of Biomarkers, and Clinical Application

Advances in Chronic Kidney Disease

Volumn 17, Issue 6, 2010, Pages 493-506

  Mischak, Harald ^a   Delles, Christian ^b   Klein, Julie ^c   Schanstra, Joost P ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c INSERM   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Biomarker; Capillary electrophoresis; CKD; Mass spectrometry; Peptides; Urine

Indexed keywords

ANTITHROMBIN III; APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CATHEPSIN D; CATHEPSIN L; CLUSTERIN; COLLAGEN TYPE 1; COLLAGEN TYPE 18; CYSTATIN C; ENDOSTATIN; FOLLITROPIN; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; PREALBUMIN; PROGESTERONE RECEPTOR; PROTEOME; SECRETORY COMPONENT; TAMM HORSFALL GLYCOPROTEIN; THROMBIN;

AGING; ANCA ASSOCIATED VASCULITIS; CAPILLARY ELECTROPHORESIS; CHRONIC KIDNEY DISEASE; COST; DATA BASE; DIABETIC NEPHROPATHY; FANCONI RENOTUBULAR SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MASS SPECTROMETRY; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY; URETEROPELVIC JUNCTION OBSTRUCTION; URINE;

EID: 78049419330     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.09.004     Document Type: Review

References (71)

1. Spahr C.S., Davis M.T., McGinley M.D., et al. Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest. Proteomics 2001, 1:93-107.
2. Peterson P.A., Evrin P.E., Berggard I. Differentiation of glomerular, tubular, and normal proteinuria: Determinations of urinary excretion of beta-2-macroglobulin, albumin, and total protein. J Clin Invest 1969, 48:1189-1198.
3. Galla J.H. IgA nephropathy. Kidney Int 1995, 47:377-387.
4. Mischak H., Coon J.J., Novak J., et al. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments. Mass Spectrom Rev 2009, 28:703-724.
5. Dakna M., He Z., Yu W.C., et al. Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: A critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1250-1258.
6. Klampfl C.W. CE with MS detection: A rapidly developing hyphenated technique. Electrophoresis 2009, 30(Suppl 1):S83-S91.
7. Kasicka V. Recent advances in CE and CEC of peptides (2007-2009). Electrophoresis 2010, 31:122-146.
8. Zurbig P., Schiffer E., Mischak H. Capillary electrophoresis coupled to mass spectrometry for proteomic profiling of human urine and biomarker discovery. Methods Mol Biol 2009, 564:105-121.
9. Fang X., Balgley B.M., Lee C.S. Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery. Electrophoresis 2009, 30:3998-4007.
10. Metzger J., Luppa P.B., Good D.M., et al. Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm. Crit Rev Clin Lab Sci 2009, 46:129-152.
11. Decramer S., Gonzalez de P.A., Breuil B., et al. Urine in clinical proteomics. Mol Cell Proteomics 2008, 7:1850-1862.
12. Lescuyer P., Hochstrasser D., Rabilloud T. How shall we use the proteomics toolbox for biomarker discovery?. J Proteome Res 2007, 6:3371-3376.
13. Good D.M., Thongboonkerd V., Novak J., et al. Body fluid proteomics for biomarker discovery: Lessons from the past hold the key to success in the future. J Proteome Res 2007, 6:4549-4555.
14. Fliser D., Novak J., Thongboonkerd V., et al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007, 18:1057-1071.
15. Schaub S., Wilkins J., Weiler T., et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004, 65:323-332.
16. Theodorescu D., Wittke S., Ross M.M., et al. Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis. Lancet Oncol 2006, 7:230-240.
17. Havanapan P.O., Thongboonkerd V. Are protease inhibitors required for gel-based proteomics of kidney and urine?. J Proteome Res 2009, 8:3109-3117.
18. Jantos-Siwy J., Schiffer E., Brand K., et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009, 8:268-281.
19. Weissinger E.M., Wittke S., Kaiser T., et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004, 65:2426-2434.
20. Mischak H., Kolch W., Aivalotis M., et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl 2010, 4:464-478.
21. Coon J.J., Zürbig P., Dakna M., et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008, 2:964-973.
22. Theodorescu D., Fliser D., Wittke S., et al. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005, 26:2797-2808.
23. Frommberger M., Zürbig P., Jantos J., et al. Peptidomic analysis of rat urine using capillary electrophoresis coupled to mass spectrometry. Proteomics Clin Appl 2007, 1:650-660.
24. Zürbig P., Renfrow M.B., Schiffer E., et al. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006, 27:2111-2125.
25. Matthiesen R. Methods, algorithms and tools in computational proteomics: A practical point of view. Proteomics 2007, 7:2815-2832.
26. Abdi H. Bonferroni and Sidak Corrections for Multiple Comparisons 2007, Sage, Thousand Oaks, CA.
27. Westfall P.H., Young S.S. Resampling-based Multiple Testing: Examples and Methods for P-Value Adjustment 1993, Wiley, New York, NY.
28. Benjamini Y., Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995, 57:125-133.
29. Mischak H., Allmaier G., Apweiler R., et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010, 2. 46ps42.
30. Mischak H, Schanstra JP: CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin Appl (in press).
31. Mischak H., Rossing P. Proteomic biomarkers in diabetic nephropathy-Reality or future promise?. Nephrol Dial Transplant 2010, 25:2843-2845.
32. Good DM, Zurbig P, Argiles A, et al: Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (in press).
33. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005, 48:1439-1444.
34. Rossing K., Mischak H., Dakna M., et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008, 19:1283-1290.
35. Snell-Bergeon J.K., Maahs D.M., Ogden L.G., et al. Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 2009, 11:1-9.
36. Alkhalaf A, Zuerbig P, Bakker SJL, et al: Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS one (in press).
37. Andersen S., Brochner-Mortensen J., Parving H.H. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003, 26:3296-3302.
38. Adler A.I., Stevens R.J., Manley S.E., et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
39. Delea T.E., Sofrygin O., Palmer J.L., et al. Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. J Am Soc Nephrol 2009, 20:2205-2213.
40. Gordois A., Scuffham P., Shearer A., et al. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 2004, 18:18-26.
41. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
42. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
43. Ruggenenti P., Fassi A., Ilieva A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951.
44. Haubitz M., Good D.M., Woywodt A., et al. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics 2009, 8:2296-2307.
45. Kistler A.D., Mischak H., Poster D., et al. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int 2009, 76:89-96.
46. Glassock R.J. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?. Am J Nephrol 2010, 31:462-465.
47. Decramer S., Wittke S., Mischak H., et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006, 12:398-400.
48. Decramer S., Bascands J.L., Schanstra J.P. Non-invasive markers of ureteropelvic junction obstruction. World J Urol 2007, 25:457-465.
49. Drube J., Zurbig P., Schiffer E., et al. Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. Pediatr Nephrol 2010, 25:1673-1678.
50. Drube J., Schiffer E., Mischak H., et al. Urinary proteome pattern in children with renal Fanconi syndrome. Nephrol Dial Transplant 2009, 24:2161-2169.
51. Metzger J, Kirsch T, Schiffer E, et al: Diagnostic marker pattern of sequenced urinary peptides for early and accurate detection of acute kidney injury. Kidney Int (in press).
52. Wittke S., Haubitz M., Walden M., et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant 2005, 5:2479-2488.
53. Zürbig P., Decramer S., Dakna M., et al. The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics 2009, 9:2108-2117.
54. Ponten F., Jirstrom K., Uhlen M. The human protein atlas-A tool for pathology. J Pathol 2008, 216:387-393.
55. Rossing K., Mischak H., Rossing P., et al. The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008, 2:997-1007.
56. Wickstrom S.A., Alitalo K., Keski-Oja J. Endostatin signaling and regulation of endothelial cell-matrix interactions. Adv Cancer Res 2005, 94:197-229.
57. Paczek L., Pazik J., Teschner M., et al. Human chronic kidney allograft rejection is accompanied by increased intraglomerular cathepsin B and L activity. Transpl Int 1994, 7(Suppl 1):S311-S313.
58. Maciel T.T., Coutinho E.L., Soares D., et al. Endostatin, an antiangiogenic protein, is expressed in the unilateral ureteral obstruction mice model. J Nephrol 2008, 21:753-760.
59. Eisenberger U., Fels L.M., Olbricht C.J., et al. Cathepsin B and L in isolated proximal tubular segments during acute and chronic proteinuria. Ren Physiol Biochem 1995, 18:89-96.
60. Wolak T., Kim H., Ren Y., et al. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009, 76:32-43.
61. Christensen B., Schack L., Klaning E., et al. Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin D. J Biol Chem 2010, 285:7929-7937.
62. Graciano M.L., Cavaglieri R.C., Delle H., et al. Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol 2004, 15:1805-1815.
63. Gang X., Ueki K., Kon S., et al. Reduced urinary excretion of intact osteopontin in patients with IgA nephropathy. Am J Kidney Dis 2001, 37:374-379.
64. Shio K., Kobayashi H., Asano T., et al. Thrombin-cleaved osteopontin is increased in urine of patients with rheumatoid arthritis. J Rheumatol 2010, 37:704-710.
65. Adams M.J., Irish A.B., Watts G.F., et al. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb Res 2008, 123:374-380.
66. Haubitz M., Wittke S., Weissinger E.M., et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005, 67:2313-2320.
67. Henze A., Frey S.K., Raila J., et al. Alterations of retinol-binding protein 4 species in patients with different stages of chronic kidney disease and their relation to lipid parameters. Biochem Biophys Res Commun 2010, 393:79-83.
68. Liz M.A., Gomes C.M., Saraiva M.J., et al. ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J Lipid Res 2007, 48:2385-2395.
69. Schmidt A., Luger A., Horl W.H. Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transplant 2002, 17:368-371.
70. Vlahou A., Allmaier G., Attwood T., et al. 2nd combined working group and management committee meeting of urine and kidney proteomics COST action. Proteomics Clin Appl 2009, 3:1017-1022.
71. Weissinger E.M., Schiffer E., Hertenstein B., et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007, 109:5511-5519.